Gossamer Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 10.38 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 63.49M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Details
| Name | Gossamer Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 162 |
| Founded | 2015 |
| Ipo Date | 2019-02-08 |
| Ceo | Faheem Hasnain |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US38341P2011 |
| Cusip | 38341P201 |
| Cik | 0001728117 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President and Chairman |
| Bryan Giraudo | Chief Operating Officer and Chief Financial Officer |
| Robert Paul Smith Jr. | Chief Commercial Officer |
| Christian Waage J.D. | Executive Vice President, Technical Operations and General Counsel |
| Jeanine Anthony | Senior Vice President of Marketing |
| Deanna Weber | Executive Vice President of Human Resources |
| Dr. Robert F. Roscigno Ph.D. | Senior Vice President of Clinical Development of Pulmonary Vascular Disease |
| Caryn L. Peterson | Chief Development Officer |
| Kelly Dawson | Senior Vice President and Program Team Lead |
| Conor O'Donovan | Senior Vice President of Regulatory Affairs |
Contact
| Address | 3115 Merryfield Row, Suite 120, San Diego, California 92121, United States |
| Phone | 858 684 1300 |
| Website | https://www.gossamerbio.com |